RDIF says rivals envy Sputnik V’s potency, lobby for sanctions - News Archive - PRIME Business News Agency - All News Politics Economy Business Wire Financial Wire Oil Gas Chemical Industry Power Industry Metals Mining Pulp Paper Agro Commodities Transport Automobile Construction Real Estate Telecommunications Engineering Hi-Tech Consumer Goods Retail Calendar Our Features Interviews Opinions Press Releases

RDIF says rivals envy Sputnik V’s potency, lobby for sanctions

MOSCOW, Jan 13 (PRIME) -- Major pharmaceutical companies are lobbying for sanctions against the Russian Direct Investment Fund (RDIF) to prevent the promotion of the Sputnik V COVID-19 vaccine, which has proven to be highly effective, head of the fund Kirill Dmitriev said at a forum on Thursday.

“The Big Pharma (companies) are actively lobbying, among other things, to impose sanctions on the RDIF… to prevent Sputnik from saving lives,” Dmitriev said.

According to Dmitriev, Western media often impede the dissemination of information about the Russian vaccine.

“People around the globe need to know the truth. Sputnik protects well against hospitalizations and deaths from Omicron, better than other vaccines.”

Dmitriev also said the fund plans to make several important announcements regarding Sputnik’s high effectiveness next week.

End

13.01.2022 18:34